52 results about "Renal cancers" patented technology

The invention discloses a plasma piRNA combination for early diagnosis of kidney cancer and application, the plasma piRNA combination for early diagnosis of kidney cancer is obtained on the basis of plasma piRNA expression profiles of Chinese population, and a kit for early diagnosis of kidney cancer is established on the basis of the plasma piRNA combination. The kit for early diagnosis of the kidney cancer can accurately predict the onset risk of early diagnosis of the kidney cancer and is beneficial to reduction of the detection cost, meanwhile, the Lasso Logistic regression model is used, the number of variables included in the model is greatly reduced, and application and popularization of the model are facilitated.

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

The invention discloses a deep learning-based laparoscopic image kidney tumor segmentation method and system, and relates to the technical field of deep learning, and the method comprises the following steps: constructing a laparoscopic kidney tumor data set RT-AMU, and dividing the RT-AMU data set into a training set and a test set according to a preset proportion; the method comprises the following steps: designing a CNN-Transform hybrid network PEEA-Net of a parallel structure, and taking the CNN-Transform hybrid network PEEA-Net as a kidney tumor initial segmentation model; inputting the training set into a kidney tumor initial segmentation model for model training until the loss function converges, and obtaining an optimized kidney tumor segmentation model; and inputting the test set into the optimized kidney tumor segmentation model to obtain a kidney tumor segmentation result of the laparoscopic image. According to the method and the system, the prediction of finer granularity can be realized when the position of the kidney tumor is accurately positioned, so that a doctor is assisted in treating the kidney cancer in the process of partial renal resection, and the complexity of the doctor in surgical operation is reduced.

Device and methods for detection of kidney cancer using urine samples are disclosed herein. The device and methods enable isolation and quantification of kidney tumor cells in urine samples from a subject in need thereof.

Provided is an antibody fusion protein, which simultaneously targets CD24, IL4R and an integrin receptor. An in-vitro assay shows that the antibody fusion protein significantly inhibits the proliferation, migration, invasion, colony formation and adhesion of renal cancer cells, also has a comprehensive and significant anti-tumor effect on gastric cancer, colon cancer and breast cancer, and has the effect of inhibiting angiogenesis. The results of a mouse tumor model of subcutaneous transplantation of MC38-hPDL1C57BL6 / J show that the antibody fusion protein combined with the PDL1 antagonist atezolizumab can significantly inhibit tumor growth. The antibody fusion protein can be used as a potential candidate drug for treating metastatic renal cell carcinoma, PDL1-overexpressing cancer, ophthalmic diseases and inflammation or autoimmune diseases.

The invention relates to a tumor-related DNA methylation marker combination, which is selected from at least one of the following: a target sequence as shown in SEQ ID NO: 1-SEQ ID NO: 10, a nucleic acid fragment with the length of at least 15 oligonucleotides or a complementary nucleic acid fragment thereof, and the nucleic acid fragment comprises at least one methylation site indicated by CG. The invention also relates to a detection kit for the methylation marker combination. According to the invention, the combination of the co-methylation states of a plurality of specific methylation regions is used for distinguishing and analyzing the occurrence of tumors, especially kidney cancer, the specific methylation combination has high sensitivity for distinguishing the occurrence of kidney cancer, and the detection method is simple, convenient and feasible. The primer pair combination of the kit overcomes the defect of false positive caused by detection mismatch of a single methylation site in the aspect of primer sequence design, and the interaction between a plurality of methylation biomarker primers and probe pair combinations is considered.

The invention relates to a kidney cancer MRI (Magnetic Resonance Imaging) image classification method based on comparative learning. The method comprises the following steps: acquiring a kidney cancer subtype data set and a corresponding kidney region label; inputting the training set into a segmentation network for kidney region segmentation and ROI extraction; performing data enhancement; constructing a double-domain contrast learning network model; obtaining a trained double-domain contrast learning network model; and performing data enhancement on a to-be-classified MRI image, and inputting the to-be-classified MRI image into the trained double-domain contrast learning network model to obtain a final kidney cancer classification result. According to the method, the features of different modal images in the same case are effectively aligned, the difference between different types of features is enhanced, the classification precision is improved, the influence caused by the difference between data sets can be reduced to a certain extent, and the generalization ability of the model is enhanced; through multi-modal image fusion, contrast learning constraint and enhancement of a sample generation strategy, the accuracy and stability of a kidney tumor classification task are effectively improved, and the method has a relatively high practical application value.

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

The invention relates to a novel cyclopeptide medicine PT-C10 with anti-tumor activity. The amino acid sequence of the novel cyclopeptide medicine PT-C10 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C10 to the 786-O kidney cancer cells is 42.23 mu M, and the IC50 of the cyclopeptide PT-C10 to the A498 kidney cancer cells is 15.53 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and the A498 and shows obvious killing efficacy. The cyclic peptide PT-C10 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

This invention belongs to the field of pharmaceutical technology and specifically relates to the use of apigenin derivatives in the preparation of anti-tumor drugs. The structure of the apigenin derivative is shown below: wherein the groups are defined as described in the specification. The compounds of this invention effectively inhibit the proliferation of renal cancer Caki-1 cells, human gastric cancer cells SNU-5, lung cancer cells, and human colon cancer cells HCT 116 in vitro. They also exhibit good inhibitory activity against renal cancer Caki-1 cells in vivo, demonstrating promising application prospects.

The present invention relates to the use of sodium pentaborate pentahydrate enriched with boron isotope (10B, 11B) as a chemotherapeutic agent thanks to its anticarcinogenic effect on renal cancer. As a result of the experimental studies performed within the scope of the invention, it has been shown that while the number of renal cancer cells decreased by 50%, this effect occurs by arresting the cell cycle and slowing down cell proliferation, therefore sodium pentaborate pentahydrate enriched with boron isotope can be used as a chemotherapeutic agent in cancer treatment.

The invention discloses a marker group for screening and diagnosing kidney cancer and application of the marker group, and belongs to the technical field of molecular biology. The marker group comprises at least four of polypeptides as shown in sequences SEQ ID NO. 1 to 38. The marker combination constructed by the invention has more excellent sensitivity and specificity when being used for auxiliary diagnosis and early screening of kidney cancer. The auxiliary diagnosis result of the kit is superior to that of imaging examination which is one of main schemes for clinical diagnosis of kidney tumors at present, and CT is enhanced (the sensitivity and the specificity are 78.67% and 87.88% respectively). The early screening result is superior to that of a high-frequency color Doppler ultrasonic instrument (the diagnosis sensitivity is 94.87%, and the specificity is 80%) which is applied to routine examination of the abdomen in physical examination at present; the sensitivity is 62.9%, and the specificity is 87.0%.

The invention provides a renal clear cell carcinoma pazopanib drug-resistant cell strain as well as a construction method and application thereof, the preservation number of the renal clear cell carcinoma drug-resistant cell strain is GDMCC NO: 65811, and the renal clear cell carcinoma drug-resistant cell strain is a pazopanib drug-resistant cell strain of 786-O. The Pazopanib is constructed in a manner of inducing the proliferation of kidney cancer cells 786-O in the Pazopanib by adopting a method of gradually increasing the concentration, and the drug resistance molecular mechanism of the Pazopanib is analyzed and read comprehensively through transcriptome, so that a new treatment idea is provided for clinically coping with the drug resistance of the Pazopanib.

The invention provides a kidney cancer risk grade analysis method based on deep learning. The method comprises the following steps: acquiring multi-modal medical data of a patient and preprocessing the multi-modal medical data to construct a training sample set; training a risk level prediction model by using the sample set until a preset condition is met; inputting data of a to-be-detected patient into the trained model to obtain a predicted risk level, if a low risk threshold is met, suggesting conventional follow-up visit, otherwise, optimizing treatment scheme parameters by adopting a multi-objective optimization algorithm, evaluating the risk level of each scheme through the model, and calculating a fitness function value in combination with a side effect score and a treatment cost; and finally outputting an optimal scheme as a clinical intervention basis. According to the invention, accurate prediction of the risk level of the kidney cancer can be realized, and the accuracy of clinical decision and the benefit-cost ratio of a treatment scheme are improved.

The invention discloses an application of a TPM3P9 protein and an RBM4 protein in kidney cancer. According to the application disclosed by the invention, high expression of the RBM4 indicates better prognosis of a renal cancer patient, and the prognosis of the patient with low expression of the TPM3P9 and high expression of the RBM4 is the best, so that the RBM4 protein or the RBM4 protein and the TPM3P9 protein can be used as a clinical diagnosis or prognosis biomarker of the renal cancer. It is also found through experiments that proliferation and growth of kidney cancer cells can be regulated and controlled by regulating and controlling the expression quantity of the TPM3P9 protein, and therefore the RBM4 protein and the TPM3P9 protein can be combined to be used for developing drugs for treating kidney cancer or proliferation and growth of kidney cancer cells.

The invention relates to a novel cyclopeptide drug PT-C07 with antitumor activity. The amino acid sequence of the novel cyclopeptide drug PT-C07 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C07 to the 786-O kidney cancer cells is 77.53 mu M, and the IC50 of the cyclopeptide PT-C07 to the A498 kidney cancer cells is 67.06 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The cyclic peptide PT-C07 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The application discloses a chimeric antigen receptor targeting CA9 and application thereof, and belongs to the technical field of biological medicine. The chimeric antigen receptor targeting CA9 comprises a CD8 alpha leader signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane domain and a CD3 zeta intracellular costimulatory signaling domain. The application adopts the anti-CA9 single-chain variable fragment as an antigen binding domain to construct a chimeric antigen receptor (CAR) molecule, and the macrophage expressing the anti-CA9 CAR can realize specific targeting and phagocytosis and killing of CA9 positive renal cancer cells, the constructed lipid nanoparticle delivery system can effectively carry a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the constructed hydrogel-liposome combined drug delivery system has the performances of relieving toxic and side effects, controllable release and hemostasis.

The invention belongs to the field of chemical synthesis, and particularly relates to a small molecule compound K-H03 with an anti-tumor effect and application of the small molecule compound K-H03 in anti-tumor drugs, and the small molecule compound has a structural formula as shown in a formula I. The compound has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a method for preparing the compound and application of the compound in preparation of antitumor drugs. Experimental results show that the IC50 of the K-H03 to the 786-O kidney cancer cells is 203.0 [mu] M, and the IC50 of the K-H03 to the A498 kidney cancer cells is 175.5 [mu] M, which indicates that the K-H03 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The K-H03 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The invention discloses a diagnostic marker for the drug resistance of kidney cancer sunitinib. The diagnostic marker for the drug resistance of kidney cancer sunitinib is selected from a group consisting of histone acetyltransferase KAT2A. The invention further discloses a kit for detecting the sunitinib drug resistance of the kidney cancer. The kit comprises a reagent for detecting the expression quantity of KAT2A. The KAT2A provided by the invention is used as a renal cancer sunitinib drug resistance diagnosis marker, has good specificity and high sensitivity, provides a new diagnosis and treatment means for renal cancer sunitinib drug resistance, is beneficial to drug resistance monitoring and avoids further invalid treatment, and has a good medical conversion prospect.

The application discloses a marker group for kidney cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-38.The marker group constructed by the application has more excellent sensitivity and specificity when used for the auxiliary diagnosis and early screening of kidney cancer.The auxiliary diagnosis result is better than that of one of main current clinical diagnosis schemes for kidney tumors, i.e., imaging examination, and enhanced CT (sensitivity and specificity are 78.67% and 87.88%, respectively).The early screening result is better than that of a high-frequency color Doppler ultrasound instrument (diagnostic sensitivity is 94.87%, and specificity is 80%) applied to the routine examination of the abdomen in a health examination; and multi-gene methylation combined analysis (sensitivity is 62.9%, and specificity is 87.0%).

The invention discloses a classification method for cross-modal renal cancer pathology upgrading based on a double-input fusion network, and the method comprises the steps: building the double-input fusion network which comprises a Bottom branch, a Upper branch and a feature fusion module, and obtaining the nonlinear enhanced high-level semantic features of an original renal cancer CT image through the original renal cancer CT image and the Upper branch; meanwhile, through the kidney cancer CT image subjected to image enhancement and Bottom branches, nonlinear enhancement high-level semantic features of the enhanced kidney cancer CT image are obtained, and finally classification of the kidney cancer CT image is completed through a feature fusion module. According to the double-input fusion network, cross-modal classification of the images can be automatically and efficiently achieved, when complex images are processed, the capturing capacity of fine-grained features is high, the calculation cost is low, the accuracy of the classification result of the images is high, and the double-input fusion network has great significance in achieving kidney cancer pathology upgrading diagnosis.

The present invention provides a pazopanib-resistant renal clear cell carcinoma cell line, a construction method, and an application thereof. The deposit number of the renal clear cell carcinoma cell line is GDMCC NO: 65811. The renal clear cell carcinoma cell line is a 786-O pazopanib-resistant cell line. The cell line is constructed by inducing the proliferation of renal cancer cells 786-O in the presence of pazopanib by gradually increasing the concentration of pazopanib. Through comprehensive transcriptome analysis, the molecular mechanism of drug resistance is interpreted, providing a new treatment strategy for clinical treatment of drug resistance.

The application belongs to the technical field of medicines, and particularly relates to application of an eight-membered selenium-containing benzazepine compound in preparation of an antitumor drug. The eight-membered selenium-containing benzazepine compound is prepared by an electrochemical method, and the reaction condition is mild and the operation is simple. The compound has certain antitumor and antibacterial activities, and particularly shows good inhibition on renal cancer cells 769-P and A498, and has a good application prospect.

The invention provides a kidney cancer marker detection method based on a nucleic acid aptamer-three-dimensional DNA nano-structure, and relates to the field of marker detection.A three-dimensional tetrahedral DNA nano-structure is synthesized through a hybridization chain reaction (HCR), a nucleic acid aptamer and the three-dimensional tetrahedral DNA nano-structure are combined to form the nucleic acid aptamer-three-dimensional DNA nano-structure, and the nucleic acid aptamer-three-dimensional DNA nano-structure is used for detecting kidney cancer markers based on the nucleic acid aptamer-three-dimensional DNA nano-structure. The kit is used for targeted detection of renal clear cell carcinoma markers; amplifying a fluorescence signal by using a hybridization chain reaction (HCR) technology; the nucleic acid aptamer-three-dimensional DNA nanostructure is applied to detection of a pathological section, and the targeted binding effect of the nucleic acid aptamer-three-dimensional DNA nanostructure in the pathological section is verified; and detecting a fluorescence signal generated by the amplification chain H2 by using a fluorescence signal detection technology.

The present invention relates to the technical field of medical devices, and particularly to an efficient renal cancer detection device. The present invention provides an efficient renal cancer detection device with a body position adjustment function. An efficient renal cancer detection device includes a base, an upper support plate, a cushion plate, etc. An upper support plate, a cushion plate, and a lower support plate are sequentially arranged above the base. The upper support plate, the cushion plate, and the lower support plate are on the same axis and provide support for the upper body, waist, and lower body of the human body respectively. It further includes a detection component, a flipping component, and a retracting component. Above the cushion plate, there is a detection component for performing imaging examinations and a retracting component for rotating and retracting the detection component. By installing movable side plates on both sides of the cushion plate in the present invention, it is possible to push the patient to turn around with a larger contact area, making the turning motion more natural and comfortable. Moreover, the side plates can be driven by an inflation component, effectively achieving the purpose of saving time and effort in flipping and improving the detection efficiency.

The invention provides a kidney cancer prognosis evaluation kit, system and method, relates to the field of in vitro detection, and designs and develops a Methylight detection primer and probe based on a DNA sample kidney methylation related marker and application of the Methylight detection primer and probe in prediction of kidney cancer prognosis. The kit has the advantages of high sensitivity and specificity, stable and reliable detection result and low cost, and has important significance for prognosis evaluation of kidney cancer.

The present disclosure provides methods for treating mesonephric cancers in a subject in need thereof comprising administering a RAF / MEK inhibitor in combination with a FAK inhibitor.

The invention belongs to the technical field of biomedicine, and relates to a methylation characteristic data detection method and a detection kit. The method comprises the following steps: extracting genome DNA from a tissue sample; performing high-throughput detection on the methylation level of the CpG site in the genome DNA to obtain a detection result; constructing a methylation characteristic analysis model based on the methylation state of the CpG site in the detection result; generating methylation feature data of the tissue sample through the model; the methylation characteristic data is used for detecting a kidney cancer specific DNA methylation marker associated with the abnormal tricarboxylic acid cycle metabolism. Through integration of multi-omics data and strict screening standards, detection of needle biopsy and surgical resection samples is supported, compatibility is high, generation and analysis of methylation data are focused, and disease diagnosis or treatment is avoided.

The present disclosure relates generally to compounds of Formulae (1-A), (1-B1), (1-C) and ((1-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, prostate, or ovarian cancer.